Welcome to our dedicated page for Dbv Technologies S A news (Ticker: DBVT), a resource for investors and traders seeking the latest updates and insights on Dbv Technologies S A stock.
DBV Technologies SA (DBVT) is a clinical-stage biopharmaceutical leader advancing epicutaneous immunotherapy (EPIT) through its innovative Viaskin platform, targeting food allergies with non-invasive precision. This page aggregates all essential updates on the company’s clinical progress, regulatory milestones, and strategic initiatives.
Investors and stakeholders gain centralized access to critical developments including phase trial results, FDA/EMA interactions, and partnership announcements. Each update is curated to provide actionable insights into DBVT’s pioneering work in allergy treatment while maintaining rigorous scientific accuracy.
Key coverage areas include Viaskin efficacy data, patent developments, and manufacturing scalability updates. The resource is designed to help users track the company’s progress from clinical research to potential commercialization without requiring cross-platform monitoring.
Bookmark this page for streamlined tracking of DBV Technologies’ advancements in redefining food allergy management through its unique skin-based immunotherapy approach.
DBV Technologies announced the screening of the first patient in the VITESSE Phase 3 clinical trial aimed at evaluating the modified Viaskin Peanut patch for peanut-allergic children aged 4 to 7 years. The trial, conducted at approximately 80 sites across the US, Canada, Australia, and Europe, will enroll 600 subjects, randomizing them 2:1 between active and placebo groups. The primary endpoint assesses treatment responders at Month 12.
Positive interactions with the FDA have supported the trial's protocol, paving the way for a potential Biologics License Application. Screening is expected to conclude in the first half of 2024, with topline results anticipated in early 2025.
DBV Technologies has filed its 2022 Annual Report on Form 10-K with the SEC and the 2022 Universal Registration Document with the AMF. These documents can be accessed via the company's website and respective regulatory authorities. DBV is focused on developing Viaskin™, an innovative technology for immunotherapy, particularly for food allergies. The company emphasizes its commitment to transforming care for food allergic patients through its unique epicutaneous immunotherapy method. Both reports are also available in printed form at the company’s headquarters.
DBV Technologies reported its 2022 financial results on March 2, 2023. The company had cash and cash equivalents of $209.2 million, a significant increase from $77.3 million in 2021, primarily driven by financing activities totaling $194.1 million and tax credit reimbursements of $26.1 million. Despite this, net loss decreased marginally from $97.8 million in 2021 to $96.3 million in 2022, translating to a net loss per share of $1.24. Operating expenses were reduced by 3%, amounting to $101.5 million. The EVOLVE study of the modified Viaskin Peanut patch showed positive caregiver feedback, supporting the patch's usability.
DBV Technologies, a clinical-stage biopharmaceutical company, will report its full year 2022 financial results and provide a business update on March 2, 2023. The company will host a conference call and live audio webcast at 5:00 p.m. ET, where participants can dial in using US: 1-866-777-2509 or International: 1-412-317-5413. The event will also be streamed on the company’s website, with a replay available afterward. DBV Technologies specializes in epicutaneous immunotherapy through its proprietary platform, Viaskin, aimed at transforming food allergy care.
DBV Technologies has announced its participation at the AAAAI 2023 Congress in San Antonio, TX, scheduled for February 24-27, where it will present two scientific posters from the Phase 3 EPITOPE study focusing on the efficacy and safety of epicutaneous immunotherapy with Viaskin Peanut in peanut-allergic children aged 1-3 years. One poster will compare data in children with and without concomitant food allergies, while the second will address those with and without atopic dermatitis. Additionally, DBV will sponsor the AAAAI Fellows-in-Training Program reception and host a booth in the exhibit hall.
DBV Technologies has announced its participation in the SBV Securities Global Biopharma Conference from February 13 to 16, 2023. The company's CEO, Daniel Tassé, will present on February 16 and will also engage in one-on-one investor meetings throughout the day. A live webcast of the presentation can be accessed via the company's website, and a replay will be available for 90 days post-event. DBV Technologies focuses on Viaskin™, an innovative platform for immunotherapy aiming to treat food allergies with ongoing trials for Viaskin Peanut. The company is headquartered in Montrouge, France, and its shares trade under the ticker DBVT on Nasdaq.
DBV Technologies released its Half-Year Report on the liquidity contract with ODDO BHF, revealing significant transaction activity and asset holdings as of December 31, 2022. The liquidity account contained 149,793 shares valued at €292,804. Since the contract's initiation on July 1, 2018, the account initially had 41,159 shares and €432,367.25. In the six-month period, 1,685 buy and 1,610 sales transactions occurred, totaling 597,406 shares worth €2,383,510 in purchases, and 553,900 shares valued at €2,245,465 in sales. DBV Technologies continues to focus on its Viaskin platform for food allergy treatments.
As of December 31, 2022, DBVT reported a total of 94,137,145 shares outstanding, indicating a stable share structure. The total number of voting rights associated is 94,137,145, with a net total of 93,966,891 voting rights after excluding shares without voting rights. This data aligns with regulatory requirements under the Autorité des Marchés Financiers and emphasizes the company’s transparency in reporting.
DBV Technologies announced the FDA has lifted the partial clinical hold on its VITESSE Phase 3 trial, evaluating the Viaskin Peanut patch in peanut-allergic children. Patient screening is expected to start in Q1 2023, with topline results anticipated in 1H 2025. The FDA requested modifications to the trial protocol to support a Biologics License Application, including changes in daily wear time and safety assessments. DBV stated it has sufficient cash to fund operations through VITESSE topline data.
DBVT has released its monthly information as of November 30, 2022, detailing the total number of voting rights and shares. The company reported a total of 94,137,145 shares, with 94,137,145 gross voting rights and 93,966,891 net voting rights after accounting for shares without voting rights. This update complies with Article 223-16 of the General Regulations of the Autorité des Marchés Financiers.
FAQ
What is the current stock price of Dbv Technologies S A (DBVT)?
What is the market cap of Dbv Technologies S A (DBVT)?
